Published in AIDS Weekly, October 27th, 1997
Most triple combination therapy to date involves protease inhibitors. Sustiva, also called efavirenz or DMP 266, is a non-nucleoside reverse transcriptase inhibitor (NNRTI), which, in this trial, is being studied in combination with Retrovir (zidovudine, AZT) and Epivir (lamivudine, 3TC) to treat HIV and AIDS. These findings were presented as part of the current Sixth European Conference on Clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.